Contributions
Abstract: EP1502
Type: ePoster
Abstract Category: Therapy - disease modifying - Neuroprotection
Background: Fingolimod, an oral sphingosine-1-phosphate receptor antagonist is effective in with the treatment of relapsing-remitting multiple sclerosis (RRMS). To this end, data on the neuroradiologic impact of fingolimod are scarce and its effects on white matter (WM) integrity were not evaluated.
Objectives: To elucidate the impact of fingolimod on WM integrity in RRMS patients treated for one year.
Methods: Brain MRI was performed by 3.0 T scanner at baseline and after one year of fingolimod treatment. Analyses of fractional anisotropy (FA), radial diffusivity (RD), axial diffusivity (AD), and mean diffusivity (MD) were carried out using tract-based spatial statistics on whole-brain and regions associated with motor or balance impairments. Changes in DTI metrics were analysed for corticospinal tracts in patients with baseline pyramidal EDSS functional score range 1.0 to 3.0, and for the inferior, middle, and superior cerebellar peduncles for patients with baseline cerebellar EDSS functional score range 1.0 to 3.0.
Results: Twenty RRMS patients, 15 females, mean ± SE age 34.5±2.2 years, disease duration 11.3±1.2 years, EDSS score 2.8±0.4, were enrolled to the study. Whole-brain and voxelwise DTI analyses showed no significant changes in DTI metrics as compared to baseline after one year of Fingolimod treatment suggesting stable disease. In patients with impaired pyramidal function (n=16), a significant increase in FA (p=0.0043) and decrease in RD (p=0.01) were found in the corticospinal tract. In patients with impaired cerebellar function (n=14), a significant increase in FA (p=0.007) and decreases in RD (p= 0.002) and MD (p=0.008) were found in the superior cerebellar peduncle.
Conclusion: Our results demonstrate improvement in WM integrity within one year of fingolimod treatment in relation to specific functional impairments.
Disclosure:
Gurevich Michael has nothing to disclose
Stone Evan has nothing to disclose
Waknin Roy has nothing to disclose
Achiron Anat has received personal compensation from Teva Pharmaceutical Industries, Sanofi-Genzyme and Novartis for serving on scientific advisory board and as a consultant.
Abstract: EP1502
Type: ePoster
Abstract Category: Therapy - disease modifying - Neuroprotection
Background: Fingolimod, an oral sphingosine-1-phosphate receptor antagonist is effective in with the treatment of relapsing-remitting multiple sclerosis (RRMS). To this end, data on the neuroradiologic impact of fingolimod are scarce and its effects on white matter (WM) integrity were not evaluated.
Objectives: To elucidate the impact of fingolimod on WM integrity in RRMS patients treated for one year.
Methods: Brain MRI was performed by 3.0 T scanner at baseline and after one year of fingolimod treatment. Analyses of fractional anisotropy (FA), radial diffusivity (RD), axial diffusivity (AD), and mean diffusivity (MD) were carried out using tract-based spatial statistics on whole-brain and regions associated with motor or balance impairments. Changes in DTI metrics were analysed for corticospinal tracts in patients with baseline pyramidal EDSS functional score range 1.0 to 3.0, and for the inferior, middle, and superior cerebellar peduncles for patients with baseline cerebellar EDSS functional score range 1.0 to 3.0.
Results: Twenty RRMS patients, 15 females, mean ± SE age 34.5±2.2 years, disease duration 11.3±1.2 years, EDSS score 2.8±0.4, were enrolled to the study. Whole-brain and voxelwise DTI analyses showed no significant changes in DTI metrics as compared to baseline after one year of Fingolimod treatment suggesting stable disease. In patients with impaired pyramidal function (n=16), a significant increase in FA (p=0.0043) and decrease in RD (p=0.01) were found in the corticospinal tract. In patients with impaired cerebellar function (n=14), a significant increase in FA (p=0.007) and decreases in RD (p= 0.002) and MD (p=0.008) were found in the superior cerebellar peduncle.
Conclusion: Our results demonstrate improvement in WM integrity within one year of fingolimod treatment in relation to specific functional impairments.
Disclosure:
Gurevich Michael has nothing to disclose
Stone Evan has nothing to disclose
Waknin Roy has nothing to disclose
Achiron Anat has received personal compensation from Teva Pharmaceutical Industries, Sanofi-Genzyme and Novartis for serving on scientific advisory board and as a consultant.